How Common Data Could Lead To Uncommon Alzheimer’s Discoveries


Imaging and genomic technologies have dramatically increased the amount of information generated and used to make clinical decisions for diseases like Alzheimer's. “There is an untapped opportunity to leverage existing data from longitudinal cohorts, from the postmortem human brain, and from clinical trials to help the field advance our shared goals more effectively than we otherwise could,” said BIO5 member Dr. Eric Reiman, Executive Director of the Banner Alzheimer’s Institute.